FDA Drug recall D-0140-2024
LET Gel (Lidocaine HCL/Epinephrine Bitartrate/Tetracaine HCL 4%/0.18%/0.5% Topical Gel), Single-use Topical Syringe, 3mL syringe, 10/pack,…
- FDA Drug
- Class III
- terminated
- Published 2023-12-13
On 2023-12-13 the FDA classified a Class III recall of LET Gel (Lidocaine HCL/Epinephrine Bitartrate/Tetracaine HCL 4%/0.18%/0.5% Topical Gel), Single-use Topical Syringe, 3mL syringe, 10/pack,… by Right Value Drug Stores, citing product Mix-up: Incorrect Product Formulation.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0140-2024 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2023-11-09 |
| Published | 2023-12-13 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Right Value Drug Stores |
| Distribution | US |
Product
LET Gel (Lidocaine HCL/Epinephrine Bitartrate/Tetracaine HCL 4%/0.18%/0.5% Topical Gel), Single-use Topical Syringe, 3mL syringe, 10/pack, Rx only, Carie Boyd Pharmaceuticals, 8400 Esters Blvd, Ste# 190, Irving, TX 75063, NDC73271-1003-1
Reason
Product Mix-up: Incorrect Product Formulation
Identifiers
| code_info | Lot#: 09202023@7, Exp 03/18/2024 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0140-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.